Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about KLRS, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
KLRS holds $82.9M in cash and short-term investments (as of Sep 30, 2026) and burns about $10.8M/quarter from operations, an estimated runway of 23 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 42 · Elevated
Based on our current operating plans, our management expects that our cash, cash equivalents and marketable securities will be sufficient to fund our operating expenses and capital expenditure requirements into 2028.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when KLRS files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Srinivas Akkaraju Director · +27,000 options |
Insider | 12,915,520 | 54.26% | 2026-05-20 |
| Samsara BioCapital GP, LLC 10% owner |
Insider | 11,448,081 | 48.09% | 2025-03-18 |
| Samsara BioCapital, L.P. | 5%+ holder (13D) | 11,448,081 | 48.09% | 2025-03-18 |
| Coastlands Capital LP | Institution (13G, 5%+) | 1,355,119 | 5.69% | 2026-10-19 |
| RTW Investments, LP | Institution (13G, 5%+) | 1,300,000 | 5.46% | 2025-12-31 |
| Napoleone Ferrara Director · +27,000 options |
Insider | 504,000 | 2.12% | 2025-03-18 |
| Samir Chandrakant Patel Director · +123,913 options |
Insider | 352,800 | 1.48% | 2025-03-18 |
| Matthew Feinsod Chief Medical Officer · +264,224 options |
Insider | 4,030 | 0.02% | 2025-03-18 |
| Amy O'Leary Vandekop VP, Corporate Controller · +10,000 options |
Insider | 948 | 0.00% | 2026-07-27 |
Share count 23,804,981 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for KLRS and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →